' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 8 Researches
8.6
USERS' SCORE
Good
Based on 10 Reviews
8.7
Supplement Facts
Serving Size: About 1/4 cup (31 g)
Amount Per Serving
%DV
Calories
180
Total Fat
13 g
17%
Saturated Fat
3 g
15%
Trans Fat
0 g
Cholesterol
0 mg
0%
Sodium
0 mg
0%
Total Carbohydrate
4 g
1%
Dietary Fiber
2 g
7%
Total Sugars
0 g
Includes 0g Added Sugars
0%
Protein
11g
Vit. D
0 mcg
0%
Calcium
8 mg
0%
Iron
4 mg
20%
Potassium
243 mg
6%
Top Medical Research Studies
9
Maresin 1 improves heart injury outcomes
Maresin 1 Attenuates Myocardium Ischemia/Reperfusion Injury via SIRT1/HMGB-1/NLRP-3-Related Mechanisms.
High relevance to cardiac treatment
We examined the potential of Maresin 1 (MaR 1), a compound known for its powerful anti-inflammatory and antioxidant properties, to combat heart ischemia/reperfusion injury (IRI). Conducting experiments on both mice and neonatal rat ventricle myocytes, we assessed how MaR 1 influences the cell death process known as pyroptosis, which is linked to IRI.
Our study revealed that administering MaR 1 before inducing IRI significantly reduced heart damage by lowering the size of heart infarcts, curbing cell death, and decreasing inflammation. The treatment led to notable improvements in heart function by acting on a signaling pathway that includes proteins like SIRT1 and HMGB-1.
In laboratory experiments, MaR 1 not only enhanced cell survival but also lessened harmful enzyme activities associated with heart damage. Moreover, when we used a SIRT1 inhibitor, it became clear that the protective effects of MaR 1 were closely tied to this pathway. This suggests that MaR 1 could offer a promising new avenue for treating cardiac IRI by targeting and reducing inflammation and cell death.
Our study revealed that administering MaR 1 before inducing IRI significantly reduced heart damage by lowering the size of heart infarcts, curbing cell death, and decreasing inflammation. The treatment led to notable improvements in heart function by acting on a signaling pathway that includes proteins like SIRT1 and HMGB-1.
In laboratory experiments, MaR 1 not only enhanced cell survival but also lessened harmful enzyme activities associated with heart damage. Moreover, when we used a SIRT1 inhibitor, it became clear that the protective effects of MaR 1 were closely tied to this pathway. This suggests that MaR 1 could offer a promising new avenue for treating cardiac IRI by targeting and reducing inflammation and cell death.
Read More
9
S100A3 protein reduces PAH risk
Risk associated circulating biomarkers S100A3 identified in congenital heart disease-associated pulmonary arterial hypertension.
Significant research on S100A3
We explored the role of S100A3, a protein that appears to play a significant role in protecting against pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD). With survival rates improving among these patients, understanding PAH's contributions to health becomes increasingly vital. Our research utilized a method known as Mendelian randomization, which helped us look for genetic influences on the levels of S100A3 in the bloodstream and its relationship with PAH risk.
By analyzing extensive genetic data from participants in the UK biobank, we discovered that higher circulating levels of S100A3 were related to a reduced risk of developing PAH. Specifically, an increase in S100A3 levels correlated with significantly lower odds of PAH. Our findings were consistent across different analytical methods and were further supported by additional data indicating a shared genetic signal between S100A3 and PAH risk.
Not only did our study highlight S100A3 as a key player, but it also provided compelling evidence that this protein holds protective qualities in the context of CHD-PAH. This discovery offers promising insights into potential therapeutic targets and strategies for managing PAH in patients with congenital heart issues.
By analyzing extensive genetic data from participants in the UK biobank, we discovered that higher circulating levels of S100A3 were related to a reduced risk of developing PAH. Specifically, an increase in S100A3 levels correlated with significantly lower odds of PAH. Our findings were consistent across different analytical methods and were further supported by additional data indicating a shared genetic signal between S100A3 and PAH risk.
Not only did our study highlight S100A3 as a key player, but it also provided compelling evidence that this protein holds protective qualities in the context of CHD-PAH. This discovery offers promising insights into potential therapeutic targets and strategies for managing PAH in patients with congenital heart issues.
Read More
9
NHE-1 inhibition improves PAH outcomes
Inhibition of Sodium/Hydrogen Exchanger-1 in the Right Ventricle and Lung Dysfunction Induced by Experimental Pulmonary Arterial Hypertension in Rats.
Moderately relevant heart disease findings
In our investigation, we examined the effects of inhibiting a specific protein, known as the sodium/hydrogen exchanger isoform 1 (NHE-1), using a compound called rimeporide in the context of pulmonary arterial hypertension (PAH) in rats. This study involved male Sprague-Dawley rats divided into two groups: one group was exposed to a substance that induces PAH, while the other served as a control.
After treating the PAH group with rimeporide for three weeks, we observed that the treatment led to improvements in both the function and structure of the heart and lungs. Notably, there was a reduction in right ventricular hypertrophy, which is the thickening of the heart's walls that often occurs in PAH.
Additionally, rimeporide displayed significant anti-inflammatory effects and improved the overall health of the pulmonary circulation. These observations suggest that by inhibiting NHE-1, we might offer a promising new way to manage heart and lung dysfunction associated with PAH. This treatment did not show any effects in the control group, highlighting the specificity of rimeporide's action in PAH.
Overall, our findings encourage further exploration of rimeporide as a potential therapeutic option for individuals suffering from PAH and related cardiovascular issues.
After treating the PAH group with rimeporide for three weeks, we observed that the treatment led to improvements in both the function and structure of the heart and lungs. Notably, there was a reduction in right ventricular hypertrophy, which is the thickening of the heart's walls that often occurs in PAH.
Additionally, rimeporide displayed significant anti-inflammatory effects and improved the overall health of the pulmonary circulation. These observations suggest that by inhibiting NHE-1, we might offer a promising new way to manage heart and lung dysfunction associated with PAH. This treatment did not show any effects in the control group, highlighting the specificity of rimeporide's action in PAH.
Overall, our findings encourage further exploration of rimeporide as a potential therapeutic option for individuals suffering from PAH and related cardiovascular issues.
Read More
Most Useful Reviews
9
Bone and skin health
Pumpkin seeds are fantastic! They enhance bone health and assist with heart disease due to their healthy fats and magnesium. I soak them overnight for better consumption.
Read More
9.5
Immunity boost
I ordered pumpkin seeds for the first time and found the quality excellent. We consume them regularly as they're beneficial for heart disease and overall immunity.
Read More
8.8
Blood pressure regulation
Excellent! The high magnesium in pumpkin seeds aids in reducing heart disease risk and maintaining healthy blood pressure.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 8 Researches
8.6
9
Nutrition Support Boosts Heart Health
Individualized Nutritional Support Improves Cardiac Function and Nutritional Status of Elderly Heart Failure Patients.
Moderate relevance to protein effects
We examined how individualized nutritional support impacts the heart health of elderly patients dealing with chronic heart failure (CHF). In our study involving 102 hospitalized CHF patients, we split participants into two groups—one receiving standard care and the other benefiting from customized nutritional guidance from a specialized nursing team.
Throughout the study, we closely monitored various health indicators, such as albumin, hemoglobin, and protein levels, as well as key measures of heart function. Our findings showed that both groups experienced improvements, but those receiving personalized nutrition demonstrated significantly better outcomes. Notably, their heart function improved, with a greater increase in left ventricular ejection fraction and a reduction in heart size markers compared to the control group.
Additionally, patients who received specialized nutritional support had lower levels of inflammatory markers and reported a higher quality of life. We observed that these participants were more satisfied with their nursing care. This evidence suggests that well-structured nutritional support, particularly focusing on protein intake and dietary factors, can play a crucial role in enhancing the health and well-being of patients with heart failure.
Throughout the study, we closely monitored various health indicators, such as albumin, hemoglobin, and protein levels, as well as key measures of heart function. Our findings showed that both groups experienced improvements, but those receiving personalized nutrition demonstrated significantly better outcomes. Notably, their heart function improved, with a greater increase in left ventricular ejection fraction and a reduction in heart size markers compared to the control group.
Additionally, patients who received specialized nutritional support had lower levels of inflammatory markers and reported a higher quality of life. We observed that these participants were more satisfied with their nursing care. This evidence suggests that well-structured nutritional support, particularly focusing on protein intake and dietary factors, can play a crucial role in enhancing the health and well-being of patients with heart failure.
Read More
9
NHE-1 inhibition improves PAH outcomes
Inhibition of Sodium/Hydrogen Exchanger-1 in the Right Ventricle and Lung Dysfunction Induced by Experimental Pulmonary Arterial Hypertension in Rats.
Moderately relevant heart disease findings
In our investigation, we examined the effects of inhibiting a specific protein, known as the sodium/hydrogen exchanger isoform 1 (NHE-1), using a compound called rimeporide in the context of pulmonary arterial hypertension (PAH) in rats. This study involved male Sprague-Dawley rats divided into two groups: one group was exposed to a substance that induces PAH, while the other served as a control.
After treating the PAH group with rimeporide for three weeks, we observed that the treatment led to improvements in both the function and structure of the heart and lungs. Notably, there was a reduction in right ventricular hypertrophy, which is the thickening of the heart's walls that often occurs in PAH.
Additionally, rimeporide displayed significant anti-inflammatory effects and improved the overall health of the pulmonary circulation. These observations suggest that by inhibiting NHE-1, we might offer a promising new way to manage heart and lung dysfunction associated with PAH. This treatment did not show any effects in the control group, highlighting the specificity of rimeporide's action in PAH.
Overall, our findings encourage further exploration of rimeporide as a potential therapeutic option for individuals suffering from PAH and related cardiovascular issues.
After treating the PAH group with rimeporide for three weeks, we observed that the treatment led to improvements in both the function and structure of the heart and lungs. Notably, there was a reduction in right ventricular hypertrophy, which is the thickening of the heart's walls that often occurs in PAH.
Additionally, rimeporide displayed significant anti-inflammatory effects and improved the overall health of the pulmonary circulation. These observations suggest that by inhibiting NHE-1, we might offer a promising new way to manage heart and lung dysfunction associated with PAH. This treatment did not show any effects in the control group, highlighting the specificity of rimeporide's action in PAH.
Overall, our findings encourage further exploration of rimeporide as a potential therapeutic option for individuals suffering from PAH and related cardiovascular issues.
Read More
9
Maresin 1 improves heart injury outcomes
Maresin 1 Attenuates Myocardium Ischemia/Reperfusion Injury via SIRT1/HMGB-1/NLRP-3-Related Mechanisms.
High relevance to cardiac treatment
We examined the potential of Maresin 1 (MaR 1), a compound known for its powerful anti-inflammatory and antioxidant properties, to combat heart ischemia/reperfusion injury (IRI). Conducting experiments on both mice and neonatal rat ventricle myocytes, we assessed how MaR 1 influences the cell death process known as pyroptosis, which is linked to IRI.
Our study revealed that administering MaR 1 before inducing IRI significantly reduced heart damage by lowering the size of heart infarcts, curbing cell death, and decreasing inflammation. The treatment led to notable improvements in heart function by acting on a signaling pathway that includes proteins like SIRT1 and HMGB-1.
In laboratory experiments, MaR 1 not only enhanced cell survival but also lessened harmful enzyme activities associated with heart damage. Moreover, when we used a SIRT1 inhibitor, it became clear that the protective effects of MaR 1 were closely tied to this pathway. This suggests that MaR 1 could offer a promising new avenue for treating cardiac IRI by targeting and reducing inflammation and cell death.
Our study revealed that administering MaR 1 before inducing IRI significantly reduced heart damage by lowering the size of heart infarcts, curbing cell death, and decreasing inflammation. The treatment led to notable improvements in heart function by acting on a signaling pathway that includes proteins like SIRT1 and HMGB-1.
In laboratory experiments, MaR 1 not only enhanced cell survival but also lessened harmful enzyme activities associated with heart damage. Moreover, when we used a SIRT1 inhibitor, it became clear that the protective effects of MaR 1 were closely tied to this pathway. This suggests that MaR 1 could offer a promising new avenue for treating cardiac IRI by targeting and reducing inflammation and cell death.
Read More
9
S100A3 protein reduces PAH risk
Risk associated circulating biomarkers S100A3 identified in congenital heart disease-associated pulmonary arterial hypertension.
Significant research on S100A3
We explored the role of S100A3, a protein that appears to play a significant role in protecting against pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD). With survival rates improving among these patients, understanding PAH's contributions to health becomes increasingly vital. Our research utilized a method known as Mendelian randomization, which helped us look for genetic influences on the levels of S100A3 in the bloodstream and its relationship with PAH risk.
By analyzing extensive genetic data from participants in the UK biobank, we discovered that higher circulating levels of S100A3 were related to a reduced risk of developing PAH. Specifically, an increase in S100A3 levels correlated with significantly lower odds of PAH. Our findings were consistent across different analytical methods and were further supported by additional data indicating a shared genetic signal between S100A3 and PAH risk.
Not only did our study highlight S100A3 as a key player, but it also provided compelling evidence that this protein holds protective qualities in the context of CHD-PAH. This discovery offers promising insights into potential therapeutic targets and strategies for managing PAH in patients with congenital heart issues.
By analyzing extensive genetic data from participants in the UK biobank, we discovered that higher circulating levels of S100A3 were related to a reduced risk of developing PAH. Specifically, an increase in S100A3 levels correlated with significantly lower odds of PAH. Our findings were consistent across different analytical methods and were further supported by additional data indicating a shared genetic signal between S100A3 and PAH risk.
Not only did our study highlight S100A3 as a key player, but it also provided compelling evidence that this protein holds protective qualities in the context of CHD-PAH. This discovery offers promising insights into potential therapeutic targets and strategies for managing PAH in patients with congenital heart issues.
Read More
9
CDC20 protects heart from DOX
CDC20 protects the heart from doxorubicin-induced cardiotoxicity by modulating CCDC69 degradation.
Relevant study on heart protection
We set out to explore how a protein called CDC20 can influence heart health, particularly in the context of doxorubicin (DOX), a powerful cancer treatment known to cause heart damage. Using heart muscle cells in a lab and mice specifically bred to lack CDC20 in their hearts, we treated them with DOX to understand the effects on heart function and health.
Our research revealed that DOX lowers the levels of CDC20, which is a key player in both cell cycle and cell death. By boosting CDC20 levels in heart cells, we found that it can significantly reduce cell death and inflammation caused by DOX. This suggests that CDC20 acts like a shield for the heart, helping to fend off the harmful effects of chemotherapy.
Interestingly, while CDC20 helped protect the heart, it did not interfere with the cancer-fighting abilities of DOX. This means that patients undergoing treatment may benefit from maintaining heart health without sacrificing the drug's effectiveness against tumors. Our findings point towards CDC20 as a potential target for therapies aimed at reducing cardiotoxicity in cancer treatments.
Our research revealed that DOX lowers the levels of CDC20, which is a key player in both cell cycle and cell death. By boosting CDC20 levels in heart cells, we found that it can significantly reduce cell death and inflammation caused by DOX. This suggests that CDC20 acts like a shield for the heart, helping to fend off the harmful effects of chemotherapy.
Interestingly, while CDC20 helped protect the heart, it did not interfere with the cancer-fighting abilities of DOX. This means that patients undergoing treatment may benefit from maintaining heart health without sacrificing the drug's effectiveness against tumors. Our findings point towards CDC20 as a potential target for therapies aimed at reducing cardiotoxicity in cancer treatments.
Read More
User Reviews
USERS' SCORE
Good
Based on 10 Reviews
8.7
9.5
Immunity boost
I ordered pumpkin seeds for the first time and found the quality excellent. We consume them regularly as they're beneficial for heart disease and overall immunity.
9
Heart health benefits
Excellent! I often purchase pumpkin seeds, which are beneficial for heart health. I enjoy them with oats or granola.
9
Bone and skin health
Pumpkin seeds are fantastic! They enhance bone health and assist with heart disease due to their healthy fats and magnesium. I soak them overnight for better consumption.
8.8
Natural anti-inflammatory
The quality of these pumpkin seeds is very good. I repurchase them as they have natural anti-inflammatory effects, benefiting my arthritis and heart disease.
8.8
Blood pressure regulation
Excellent! The high magnesium in pumpkin seeds aids in reducing heart disease risk and maintaining healthy blood pressure.
